{
  "id": 483764,
  "title": "Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal",
  "url": "https://urgent.news/2026/08/10/jazz-to-buy-rare-epilepsy-drugmaker-in-potentially-1-3b-deal",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-10T15:36:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/jazz-actio-acquisition-deal-rare-neurological-epilepsy/827409/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Actio Biosciences, which will receive $820 million up front in the deal, adds to a major upswing in private biotech buyouts seen throughout this year.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "STAT News",
        "title": "STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more",
        "url": "https://urgent.news/2026/08/10/stat-pharmalittle-were-reading-about-a-sanofi-drug-shortage-a-jazz",
        "published": "2026-08-10T13:24:23.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}